Lonjon Guillaume, Ross Nicolas, Dhenin Alexandre, Vassal Matthieu, Gourari Anne, Bouic Nicolas, Bonnal Aurélien
Orthosud, Clinique Saint Jean Sud de France, 34430 St Jean de Vedas, Montpellier, France.
Hospital Privado Universitario de Córdoba, Córdoba, Argentina.
Brain Spine. 2025 Aug 6;5:104379. doi: 10.1016/j.bas.2025.104379. eCollection 2025.
Postoperative pain management is a challenge after lumbar spine surgery. Erector spinae plane (ESP) block is one solution and seems to limit opioid consumption after lumbar fusion. This RCT explored the effectiveness of ESP block versus placebo in non-instrumented spine surgery within an ERAS program.
The hypothesis suggested the superiority of ESP block across all endpoints, emphasizing its potential as a safe and effective element.
In this prospective, single-center, randomized, double-blinded controlled trial using a 1:1 allocation with an intent-to-treat, patients undergoing non-fusion lumbar surgery for one or two levels were included from January to November 2022. Ultrasound-guided ESP block was performed by an anesthesiologist injecting levobupivacaine or saline solution (placebo). The primary outcome was total morphine consumption at 72 h.
We included 100 individuals (50 in each arm). Total morphine consumption at 72 h did not differ between the ESP block and placebo groups, nor did cumulative pain score, intraoperative sufentanil administration, 1-month ODI and pain scores. In the daily analysis, morphine consumption was greater in the placebo group at day 0, and in the ESP block group from day 1 to day 3, without significance. The pain scores throughout the first 72 postoperative hours were <3/10 in both groups.
The groups did not differ in morphine consumption at 72 h postoperatively. Increased morphine dose after the first 24 h in the ESP block group could suggest a rebound effect. In patients undergoing non-instrumented spine surgery, the ESP block does not confer additional analgesic benefits.
腰椎手术后的疼痛管理是一项挑战。竖脊肌平面(ESP)阻滞是一种解决方案,似乎可以减少腰椎融合术后的阿片类药物消耗。这项随机对照试验探讨了在加速康复外科(ERAS)计划中,ESP阻滞与安慰剂相比在非内固定脊柱手术中的有效性。
该假设表明ESP阻滞在所有终点指标上均具有优越性,强调了其作为一种安全有效因素的潜力。
在这项前瞻性、单中心、随机、双盲对照试验中,采用1:1分配并按意向性分析,纳入了2022年1月至11月接受一或两个节段非融合性腰椎手术的患者。由麻醉医生进行超声引导下的ESP阻滞,注射左旋布比卡因或生理盐水溶液(安慰剂)。主要结局指标是72小时时的吗啡总消耗量。
我们纳入了100名个体(每组50名)。ESP阻滞组和安慰剂组在72小时时的吗啡总消耗量、累积疼痛评分、术中舒芬太尼用量、1个月时的功能障碍指数(ODI)和疼痛评分均无差异。在每日分析中,安慰剂组在第0天的吗啡消耗量更大,而ESP阻滞组在第1天至第3天的吗啡消耗量更大,但差异无统计学意义。两组术后前72小时的疼痛评分均<3/10。
两组术后72小时的吗啡消耗量无差异。ESP阻滞组在最初24小时后吗啡剂量增加可能提示有反跳效应。在接受非内固定脊柱手术的患者中,ESP阻滞并未带来额外的镇痛益处。